Cesca Therapeutics came into being with the merger of ThermoGenesis Corporation with TotipotentRx Corporation in 2014. The parent company is Boyalife (Hong Kong) Limited thereby making the firm ineligible for further SBIR involvement. Cesca is organized primarily around autologous cell-based therapeutics for use in regenerative medicine - developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. The firm supplies products targeting the worldwide adult stem cell market offering automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues from cord blood and bone marrow used in the practice of regenerative medicine. Regenerative medicine is a field that aims to repair or restore lost or damaged tissue and cell function using cell-based therapies. The company's core offerings include the AXP AutoXpress Platform for processing of cord blood; and BioArchive System, an automated cryogenic device used by cord blood banks for the cyropreservation and archiving of cord blood stem cell units for transplant. Its offerings also comprise MXP MarrowXpress, which is used for isolating stem cells from bone marrow, and the Res-Q 60 BMC, a point-of-care bone marrow stem cell processing system. In addition, ThermoGenesis markets the Thermoline product line, which includes the ultra-rapid plasma Thermoline Freezer and Thermoline Thawer
